Iroko Pharmaceuticals Announces Key Patent Grant For ZORVOLEX™

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

PHILADELPHIA--(BUSINESS WIRE)--Iroko Pharmaceuticals, LLC, a global specialty pharmaceutical company dedicated to advancing the science of analgesia, announced today that the first patent has been issued by the United States Patent and Trademark Office for the composition of matter and formulation of ZORVOLEX™ (diclofenac) capsules. ZORVOLEX was approved in October 2013 by the U.S. Food and Drug Administration (FDA) for the treatment of mild to moderate acute pain in adults.

Help employers find you! Check out all the jobs and post your resume.

MORE ON THIS TOPIC